Search

Charles N Serhan

from Needham, MA
Age ~70
Get Report
Also known as:
Chas N Serhan
Phone and address:
23 Smith St, Needham, MA 02492
(781) 400-1348
Related to:
Seth R Goldstein, 70Eugene Goldsmith, 71
Connected to:
Javier Serhan, 52Rona N Serhan, 50Mohamed Serhane, 64I Seri, 40Istvan Seri, 73Paul G Seri, 48Ila Serianne, 40Nancy A Serianni, 98Virl C Seribo, 43Carol J Serici, 65

Charles Serhan Phones & Addresses

  • 23 Smith St, Needham, MA 02492 (781) 400-1348
  • Boston, MA
  • 51 Crown Ridge Rd, Wellesley, MA 02482 (781) 235-9264
  • Clark, NJ
  • 99 Needham St, Newton Highlands, MA 02461 (617) 916-0221
  • Brookline, MA
  • 23 Smith St, Needham, MA 02492

Work

Company: Harvard university Jul 1986 Position: Professor --biomedical scientist

Education

Degree: High school graduate or higher

Skills

Event Planning • Microsoft Office • Management • Microsoft Word • Research • Microsoft Excel • Social Media • Public Speaking • Higher Education • Customer Service

Industries

Higher Education

Resumes

Resumes

Charles Serhan Photo 1

Professor --Biomedical Scientist

View page
Location:
Boston, MA
Industry:
Higher Education
Work:
Harvard University
Professor --Biomedical Scientist
Skills:
Event Planning
Microsoft Office
Management
Microsoft Word
Research
Microsoft Excel
Social Media
Public Speaking
Higher Education
Customer Service

Business Records

Name / Title
Company / Classification
Phones & Addresses
Charles Serhan
Director
Resolvyx Pharmaceuticals, Inc
Noncommercial Research Organization
222 3 St, Cambridge, MA 02142

Publications

Us Patents

Regulation Of Phospholipase D Activity

View page
US Patent:
6353026, Mar 5, 2002
Filed:
Mar 14, 2000
Appl. No.:
09/525157
Inventors:
Charles N. Serhan - Wellesley MA
Assignee:
Brigham and Womens Hospital - Boston MA
International Classification:
A61K 3120
US Classification:
514560, 514558
Abstract:
Novel inhibitors of polyisoprenyl phosphate signaling regulates phopholipase D activity.

Inhibition Of Tnf-()-Initiated Neutrophil Response

View page
US Patent:
6387953, May 14, 2002
Filed:
Mar 14, 2000
Appl. No.:
09/525291
Inventors:
Charles N. Serhan - Wellesley MA
Assignee:
Brigham and Womens Hopsital - Boston MA
International Classification:
A61K 3120
US Classification:
514560, 514558
Abstract:
The impact of lipoxin A (LXA ) and aspirin-triggered-lipoxins (ATL) was investigated in tumor necrosis factor (TNF)-initiated neutrophil (PMN) responses in vitro and in vivo using metabolically stable LX analogs. At concentrations as low as 1-10 nM, the LXA and ATL analogs each inhibited TNF-stimulated superoxide anion generation and IL-1 release by human PMN.

Screening Methods For Presqualene Disphosphate Analogs

View page
US Patent:
6416965, Jul 9, 2002
Filed:
Dec 13, 2000
Appl. No.:
09/736005
Inventors:
Charles N. Serhan - Wellesley MA
Bruce D. Levy - West Roxbury MA
Assignee:
Brigham and Womens Hospital - Boston MA
International Classification:
C12Q 134
US Classification:
435 18, 435 25
Abstract:
The present invention is directed to presqualene diphosphate (PSDP) analogs having an active region of natural PSDP and a metabolic transformation region resistant to rapid intracellular inactivation in vivo. For example, PSDP and its stable analogs can inhibit neutrophil signal transduction events in cellular activation that result in the generation of active oxygen species, regulation of leukocyte adherence, both homotypic (leukocyteâleukocyte) or heterotypic adherence with leukocytes and epithelial cells of mucosal origin or endothelial cells of vascular origin. These analogs can also be used to regulate leukocyte-dependent tissue injury.

Prevention Of Neutrophil Recruitment

View page
US Patent:
6433202, Aug 13, 2002
Filed:
Mar 14, 2000
Appl. No.:
09/525742
Inventors:
Charles N. Serhan - Wellesley MA
Assignee:
Brigham and Womens Hospital - Boston MA
International Classification:
C07C 5900
US Classification:
554213, 554219, 558303, 568 21, 568 22, 568 28
Abstract:
Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.

Leukotriene B4 Receptor Transgenic Mice

View page
US Patent:
6455755, Sep 24, 2002
Filed:
Jan 11, 2001
Appl. No.:
09/758649
Inventors:
Charles N. Serhan - Wellesley MA
Assignee:
Brigham and Womens Hospital - Boston MA
International Classification:
G01N 3300
US Classification:
800 3, 800 18
Abstract:
The present invention describes a non-human transgenic mammal that produces in its leukocytes, a recombinant human leukotriene B receptor (BLTR), having physiological activity of human BLTR. The transgenic mammal has stably integrated into its genome an exogenous gene construct which includes (A) 5â expression regulating sequences, including a BLTR specific promoter, (B) DNA encoding the BLTR and a signal sequence effective in directing overexpression of the BLTR into leukocytes of the transgenic mammal and (C) 3â regulatory sequences that result in the overexpression of the DNA in the leukocytes. In one embodiment, (A), (B), and (C) are operably linked in the gene construct to obtain production of the BLTR in the leukocytes and overexpression thereof in the transgenic mammal.

Modulation Of Inflammation Related To Columnar Epithelia

View page
US Patent:
6458839, Oct 1, 2002
Filed:
Oct 5, 2001
Appl. No.:
09/972419
Inventors:
James L. Madara - Winchester MA
Charles N. Serhan - Boston MA
Sean P. Colgan - Newton MA
Assignee:
The Brigham and Womens Hospital - Boston MA
International Classification:
A61K 3123
US Classification:
514552, 514559
Abstract:
This invention provides pharmaceutical compositions containing lipoxin compounds and therapeutic uses for the compounds in treating or preventing a disease or condition associated with columnar epithelial inflammation. The invention also discloses methods for screening for compounds useful in preventing columnar epithelial inflammation.

Lipoxin Compounds And Their Use In Treating Cell Proliferative Disorders

View page
US Patent:
6569075, May 27, 2003
Filed:
Oct 1, 2001
Appl. No.:
09/968445
Inventors:
Charles N. Serhan - Needham MA
Assignee:
Brigham and Womens Hospital - Boston MA
International Classification:
A01N 3700
US Classification:
574560, 554213, 562584
Abstract:
Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed.

Lipoxin Compounds And Their Use In Treating Cell Proliferative Disorders

View page
US Patent:
6620919, Sep 16, 2003
Filed:
Jun 19, 2002
Appl. No.:
10/175268
Inventors:
Charles N. Serhan - Needham MA
Assignee:
The Brigham and Womens Hospital - Boston MA
International Classification:
C07C 5900
US Classification:
534213, 514352, 514560, 522586
Abstract:
Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which characterizes diseases such as cancer, are also disclosed.

Isbn (Books And Publications)

Lipoxins: Biosynthesis, Chemistry, and Biological Activities

View page
Author

Charles N. Serhan

ISBN #

0306428199

Molecular and Cellular Basis of Inflammation

View page
Author

Charles N. Serhan

ISBN #

0896035956

Control profile
Charles N Serhan from Needham, MA, age ~70 Get Report